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Cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) is a master anti-apoptotic regulator and resistance 
factor that suppresses tumor necrosis factor-α (TNF-α), Fas-L, and TNF-related apoptosis-inducing ligand (TRAIL)-induced apo pto-
sis, as well as apoptosis triggered by chemotherapy agents in malignant cells. c-FLIP is expressed as long (c-FLIPL), short (c-FLIPS), 
and c-FLIPR splice variants in human cells. c-FLIP binds to FADD and/or caspase-8 or -10 and TRAIL receptor 5 (DR5) in a ligand-
dependent and -independent fashion and forms an apoptosis inhibitory complex (AIC). This interaction in turn prevents death-induc-
ing signaling complex (DISC) formation and subsequent activation of the caspase cascade. c-FLIPL and c-FLIPS are also known 
to have multifunctional roles in various signaling pathways, as well as activating and/or upregulating several cytoprotective and pro-
survival signaling proteins including Akt, ERK, and NF-kB. Upregulation of c-FLIP has been found in various tumor types, and its 
silencing has been shown to restore apoptosis triggered by cytokines and various chemotherapeutic agents. Hence, c-FLIP is an im-
portant target for cancer therapy. For example, small interfering RNAs (siRNAs) that specifically knockdown the expression of c-FLIPL 
in diverse human cancer cell lines augmented TRAIL-induced DISC recruitment and increased the efficacy of chemotherapeutic 
agents, thereby enhancing effector caspase stimulation and apoptosis. Moreover, small molecules causing degradation of c-FLIP 
as well as decreasing mRNA and protein levels of c-FLIPL and c-FLIPS splice variants have been found, and much effort is focused 
on developing other c-FLIP-targeted cancer therapies. This review focuses on (1) the anti-apoptotic role of c-FLIP splice variants 
in preventing apoptosis and inducing cytokine and chemotherapy drug resistance, (2) the molecular mechanisms and factors that 
regulate c-FLIP expression, and (3) modulation of c-FLIP expression and function to eliminate cancer cells or increase the efficacy 
of anticancer agents. This article is part of a Special Issue entitled “Apoptosis: Four Decades Later”.
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INTRODUCTION
The FADD-like interleukin-1β–converting enzyme 
(FLICE)-inhibitory (c-FLIP) proteins negatively regulate 
the signaling complex downstream of death recep-
tors. In this review, I discuss (1) apoptosis signaling 
pathways and the role of c-FLIP isoforms as critical 
anti-apoptotic and drug resistance factors, (2) assess 
the potential for improving the outcome of cancer 
therapy by targeting c-FLIP and exploring the possi-
bility of increasing its degradation and/or decreasing 
its expression to provide a safer approach to treat 
cancer, and (3) discuss novel c-FLIP targeted agents 
for cancer therapy that improve the efficacy of TRAIL 
and cytotoxic drugs.
APOPTOSIS SIGNALING PATHWAYS 
Apoptosis is the orderly and tightly regulated cellular 
programmed cell death involving signal transduction 
pathways that induce cells to self-destruct during embry-
onic development, or in response to environmental haz-
ards (e.g., radiation-induced DNA damage) or anticancer 
therapeutics. Apoptosis pathways provide control against 
cancer development, but specific mutations enable 
malignant cells to escape apoptosis and lead to tumor 
formation. Two major well-studied pathways, the intrin-
sic or mitochondrion-initiated pathway and the extrinsic 
or cell surface death receptors pathway, are involved 
in apoptosis (Fig. 1) [1–3]. In the mitochondrial pathway, 
cytochrome c, certain caspases, apoptosis-inducing 
factor, Smac/DIABLO, and other apoptosis-inducing fac-
tors are released from the mitochondrial intramembrane 
space to the cytosol [4]. Once released, cytochrome 
c and dATP bind to apoptotic proteinase-activating 
factor-1 (Apaf-1), and this complex along with adenine 
nucleotides promote procaspase-9 autoactivation [5], 
which in turn activates caspases-2, -3, -6, -7, -8, and 
-10. Apoptosis triggered by various stimuli requires direct 
activation of Bax and BAK at the mitochondria by a mem-
ber of the Bcl-2 homology domain-3 (BH3)-only family 
of proteins including Bid, Bim, or PUMA [6]. The various 
anti- and pro-apoptotic members of the Bcl-2 family form 
an interactive network that finally regulates the release 
of apoptosis triggering factors such as cytochrome 
c to the cytoplasm [7]. Apoptosis initiated by the endo-
plasmic reticulum (ER) stress signaling pathway is also 
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mainly dependent on the release of cytochrome c into 
the cytosol [8]. This release is associated with opening 
the permeability transition pore (PTP) and a collapse 
of mitochondrial transmembrane potential (∆Ψm) due 
to the intake of Ca2+ following its release into the cytosol 
from the ER. Certain members of the Bcl-2 family on the 
ER appear to have a comprehensive function in the main-
tenance of ER homeostasis, participation in ER stress 
signal transduction pathways, and apoptosis [8].
In the extrinsic or death receptor-mediated apoptosis 
pathway (e.g., Fas/Fas ligand interaction, tumor necrosis 
factor-α [(TNF-α)/TNF receptor 1 (TNFR1), or TRAIL/
DR5 interaction and cell death], the initiator caspa-
ses-8 and -10 activate the downstream caspases includ-
ing caspase-3 [9–11]. Active caspases-8 and -10 are 
known to cleave a pro-apoptotic Bcl-2 family member, 
Bid, and the truncated Bid induces mitochondrial cy-
tochrome c release [26–29], thereby linking the two 
pathways. After activation, both caspases-8 and -9 ac-
tivate caspase-3, which in turn cleaves other caspases 
and many cellular proteins [2, 12–14]. Another pathway 
related to the intrinsic apoptotic pathway has also been 
identified [15]. In this pathway, BID is cleaved in response 
to several death-inducing stimuli (staurosporine, UV ra-
diation, cycloheximide, etoposide) and this BID cleavage 
is blocked by Bcl-2, suggesting that degradation of BID 
occurred distal to cytochrome c release. Moreover, ad-
dition of cytochrome c to Jurkat post-nuclear extracts 
triggered cleavage of BID at Asp-59 which was catalyzed 
by caspase-3 rather than caspase-8. These results 
provide evidence that caspase-3 mediated cleavage 
of BID represents a feedback loop for the amplification 
of mitochondrial cytochrome c release during cytotoxic 
drug- and UV radiation-induced apoptosis [15].
CELLULAR FLICE-LIKE INHIBITORY 
PROTEIN (C-FLIP)
Structure of c-FLIP. The anti-apoptotic protein 
c-FLIP is a death effector domain (DED)-containing 
protein that is recruited to the DISC and regulates acti-
vation of caspases-8 and -10 in the death receptor sig-
naling pathways (Fig. 1). c-FLIP has 13 distinct spliced 
variants, three of which are expressed as proteins: the 
26 kDa short form (c-FLIPS), the 24 kDa form of c-FLIP 
(c-FLIPR), and the 55 kDa long form (c-FLIPL) [16–18] 
(Fig. 2). The structures of c-FLIPS and the viral v-FLIP 
proteins are similar, except that the two DEDs of c-FLIPS 
are followed by 20 amino acids that appear to be crucial 
for its ubiquitaation and targeting for proteasomal deg-
radation [11, 16–18]. c-FLIPR also contains two DEDs but 
lacks the additional carboxy (C)-terminal amino acids 
that are present in c-FLIPS. The C-terminus of c-FLIPL 
is longer than that of c-FLIPS and closely resembles the 
structure of caspases-8 and -10 [11, 16–18], but this 
region of c-FLIPL does not contain a functional cas-
pase domain. This lack of caspase activity is the result 
of several amino acid substitutions, particularly the 
crucial cysteine residue in the catalytic domain which 
is necessary for the catalytic activity of caspases [11, 
16]. Additionally, c-FLIPL has a caspase-8 cleavage site 
at position Asp-376 (LEVD); c-FLIPL cleavage at this 
site produces the proteolytic fragment variant p43c-
FLIP [11, 16–18]. The C-terminal region of c-FLIPS and 
c-FLIPR play a crucial role in ubiquitnation and degra-
dation as well as the anti-apoptotic function of these 
isoforms [11, 16–18]. In humans, the decision to make 
c-FLIPS or c-FLIPR is defined by a single nucleotide 
polymorphism in a 3´ splice site of the c-FLIP gene. 
An intact splice site directs production of c-FLIPS, but 
the splice-dead variant causes production of c-FLIPR 
[19]. Because of differences in protein translation rates, 
higher levels of c-FLIPS protein are produced compared 
with c-FLIPR [19]. The three c-FLIP variants can interact 
with the adaptor protein FADD.
Fig. 1. Apoptosis pathways and roles of c-FLIP in preventing 
apoptosis. TRAIL interaction with DR4 and DR5 transduces the 
death receptor (extrinsic) and mithochondrial apoptosis signal-
ing pathways through activation of caspases-8 and -10 (see the 
text for detailed information). c-FLIP isoforms are major anti-
apoptotic proteins that suppress caspase-8 and -10 activation, 
and therefore prevent the downstream apoptosis cascade
Fig. 2. Structures of c-FLIP variants. Three c-FLIP variants, c-
FLIPL, c-FLIPS, and c-FLIPR, contain two death effector domains 
(DEDs) at their N termini. In addition to two DEDs, c-FLIPL con-
tains a large (p20) and a small (p12) caspase-like domain without 
catalytic activity. c-FLIPS and c-FLIPR consist of two DEDs and 
a small C terminus. Depending on its cellular level at the DISC, 
c-FLIPL may act as an anti-apoptotic or pro-apoptotic factor [9, 
16, 18]. c-FLIPS, c-FLIPS, c-FLIPR, and two cleavage products 
of c-FLIP (p43-FLIP and p22-FLIP) act as anti-apoptotic proteins 
[9, 16, 18]. p43-FLIP and p22-FLIP are generated from c-FLIPL 
by procaspase-8 cleavage at D376 [9] (adapted from [9, 16, 18])
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c-FLIP transcription and translation. c-FLIP 
can be transcriptionally activated by various stimuli. 
These include TNF ligands, growth factors, interleu-
kins, chemokines, and chemotherapeutic agents 
[11]. Several transcription factors are known to tran-
scriptionally regulate the c-FLIP gene [11, 18]. These 
include NF-κB, p53 tumor suppressor protein, p63, 
E2F1, c-myc, IRF5, c-Fos, nuclear factor of activated 
T cells (NFAT), heterogeneous nuclear ribonucleo-
protein K (hnRNP K), the forkhead transcription factor 
FOXO3a, early growth response-1 transcription factor 
(EGR1), androgen receptor (AR), E2F1, AP-1, and SP1. 
While NF-κB, p63, NFATc2, EGR1, hnRNP K, AR and 
SP1 induce c-FLIP, c-myc, FOXO3a, c-Fos, IRF5, and 
SP3 suppress c-FLIP transcription [11, 18]. p53 may 
transcriptionally upregulate the c-FLIP gene and also 
promote the degradation of c-FLIP protein [16]. More-
over, Gli2 transcription factor upregulates c-FLIPS and 
c-FLIPL [20]. c-FLIPS is highly induced upon activation 
of T cells, primarily via the calcineurin-NFAT pathway 
[16]. The human T-cell leukemia virus type 1 (HTLV-
1) Tax protein upregulates c-FLIP in HTLV-1-infected 
cells through activation of NF-κB [6]. c-FLIPS is also 
upregulated at the translational level and causes TRAIL 
resistance in glioblastoma multiforme (GBM) cells due 
to activation of the Akt mammalian target of rapamycin 
(mTOR)-p70 S6 kinase 1 (S6K1) pathway [21, 22]. 
Conversely, inhibition of mTOR or its target S6K1 sup-
pressed polyribosomal accumulation of c-FLIPS mRNA, 
c-FLIPS protein expression, and promoted TRAIL resis-
tance in GBM cells. Moreover, it has been shown that 
Rocaglamide (Roc) sensitizes resistant adult T-cell 
leukemia/lymphoma (ATL) cells to DR4- and DR5-me-
diated apoptosis by translational suppression of c-FLIPS 
through inactivation of the translation initiation factor 
4E (eIF4E) [16, 23].
c-FLIP degradation. Both c-FLIPL and c-FLIPS 
isoforms are short-lived proteins that are predominately 
degraded by the ubiquitin-proteasome degradation 
system [11, 16, 18]. Both c-FLIP isoforms can be de-
graded by the proteasome. However, c-FLIPS is par-
ticularly sensitive to ubiquitination and proteasomal 
degradation, partly due to two crucial lysine residues 
in the C-terminal 20 amino acids that are unique 
to c-FLIPS [24]. The sensitivity of c-FLIPS to ubiquitin-
mediated degradation adds a novel concept to DISC 
regulation and its control of apoptosis [24]. c-FLIPL and 
c-FLIPS levels are also regulated by JNK activation via 
the E3 ubiquitin ligase Itch [11, 18, 25]. Phosphoryla-
tion events also play important roles in the regulation 
of c-FLIP protein levels. For instance, protein kinase C 
(PKC) phosphorylation at the serine 193 (S193) residue 
of c-FLIPS inhibits its polyubiquitination, stabilizes c-
FLIPS levels, and increases cell survival [66]. S193 phos-
phorylation is markedly increased by treatment with the 
PKC activator 12-O-tetradecanoylphorbol-13-acetate 
and decreased by inhibition of PKCα and PKCβ. Phos-
phorylation of the S193 residue also decreased the 
ubiquitination of c-FLIPL but did not affect its stability, in-
dicating that S193 phosphorylation has a different func-
tion in c-FLIPL than in c-FLIPS. Moreover, pretreatment 
with the PKCδ-selective inhibitor rottlerin or transfection 
with PKCδ siRNA inhibited phorbol myristate acetate 
(PMA)-induced c-FLIP expression, which identifies 
a role for PKCδ in c-FLIP induction [26].
Upregulation of c-FLIP in human cancers. In-
creased expression of c-FLIP isoforms has been shown 
in cell lines from various types of cancer including 
colorectal [11, 16, 18]. Elevated levels of c-FLIP in tu-
mor tissue from patients with colorectal cancer [28, 
29], bladder urothelial cancer [30], cervical cancer 
[31], Burkitt’s lymphoma [32], non-Hodgkin’s lym-
phoma [33], head and neck squamous cell carcinoma 
(HNSCC) [34], and hepatocellular cancers [35] have 
been correlated with a poor clinical outcome and could 
be a reliable prognostic factor in these types of can-
cer. c-FLIP upregulation is also seen in gastric cancer 
and plays an important role in lymph node metastasis, 
which ultimately contributes to tumor progression 
[36]. c-FLIP isoforms are also expressed in pancreatic 
intraepithelial neoplasms as well as pancreatic ductal 
adenocarcinomas, whereas normal pancreatic ducts 
were consistently negative for c-FLIP expression [37]. 
McCourt et al. [38] reported that c-FLIP expression 
was increased in high-grade prostatic intraepithelial 
neoplasia (HGPIN) and prostate cancer tissue rela-
tive to normal prostate epithelium. Significantly, these 
authors found that maximal c-FLIP expression was 
detected in castrate-resistant prostate cancer (CRPC).
C-FLIP FUNCTION
c-FLIP prevents apoptosis. Initial studies with 
animal models have revealed that c-FLIP plays an im-
portant role in T-cell proliferation and heart develop-
ment [39, 40]. Moreover, abnormal c-FLIP expression 
has been found in various diseases such as cancer, 
multiple sclerosis, Alzheimer’s disease, diabetes mel-
litus, and rheumatoid arthritis [11, 17]. c-FLIP is also 
thought to be the main causal factor of “immune 
escape” [41]. c-FLIP is involved in TRAIL, Fas, TNF-α, 
and chemotherapeutic drug resistance in a wide range 
of human malignancies [11, 16–18]. Moreover, studies 
using c-FLIP-deficient mice support a dual function for 
c-FLIPL by confirming a role for c-FLIP in Fas L, TNF-
α-induced apoptosis and revealing that c-FLIP has 
a similar function to caspase-8 in heart development 
[40]. Nevertheless, extensive literature encompassing 
diverse types of human cancer cells now indicates 
that the action of c-FLIP is generally anti-apoptotic 
in cancer cells. Furthermore, interference with c-FLIP 
expression sensitizes tumor cells to death ligands and 
chemotherapy in experimental models [11, 18, 42–45]. 
In addition to its function as an apoptosis modulator, c-
FLIP exerts other cellular functions including increased 
cell proliferation and tumorigenesis [11, 17–19].
The structural differences between human c-FLIP 
variants indicate distinct regulatory roles for c-FLIPL 
and c-FLIPS in apoptosis. c-FLIPS inhibits TRAIL-
induced DISC formation and apoptosis [24, 45], while 
c-FLIPL is responsible for the dual functions described 
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above whereby it inhibits Fas-induced caspase-8 ac-
tivation when expressed at high levels, but enhances 
caspase-8 activation when its expression level is low 
[11, 18]. c-FLIPS also suppresses apoptosis by inhibit-
ing caspase-8 activation [46, 47]. Moreover, c-FLIPS 
inhibits oxaliplatin-induced apoptosis through the 
sustained XIAP protein level and Akt activation [48]. 
We have demonstrated that c-FLIPL interacts with 
DR5, FADD, and caspase-8 forming an apoptotic in-
hibitory complex (AIC) in MCF-7 breast cancer cells 
[49]. Moreover, silencing the c-FLIP gene by a specific 
siRNA leads to (1) death ligand-independent but DR5-, 
FADD-, and caspase-8- and -9-dependent apoptosis 
in these cells, and (2) the knockdown of c-FLIP ex-
pression inhibits breast cancer cell proliferation and 
triggers spontaneous apoptosis by activating both 
the death receptor and mitochondrial pathways [49]. 
Our data support the previous report by Jin et al. [50] 
demonstrating that the peptide corresponding to the 
DR5 binding domain of c-FLIPL induces apoptosis 
in cancer cells. It is possible that inhibiting the interac-
tion of DR5 and c-FLIPL by peptides or small molecule 
inhibitors could provide a mechanism by which tumor-
selective apoptosis can be achieved. 
c-FLIP activates cytoprotective pathways. 
As shown in Fig. 3, c-FLIP activates several cytopro-
tective signaling pathways involved in regulating cell 
survival, proliferation, and carcinogenesis. Overex-
pression of c-FLIPL activates NF-κB and ERK signaling 
by binding to adaptor proteins in each pathway, such 
as TNFR-associated factors 1 (TRAF1) and 2 (TRAF2), 
receptor-interacting protein 1 (RIP), and Raf-1 [19, 
51] (see Fig. 3). The caspase-8 processed N-terminal 
fragment of c-FLIPL (p43cFLIP) is more efficient than 
c-FLIPL at recruiting TRAF2 and RIP1, leading to more 
robust NF-κB activation [19, 20, 52, 53]. Golks et al. [54] 
found that in nonapoptotic cells, c-FLIP and the pro-
caspase-8 heterodimer result in a novel NH2-terminal 
fragment of c-FLIP (p22-FLIP) which is the key mediator 
of NF-κB activation by binding to the IKK complex. More-
over, TNF-α-mediated JNK activation increases turnover 
of NF-κB-induced c-FLIP [25]. This is not the result 
of direct c-FLIP phosphorylation, but rather depends 
on JNK-mediated phosphorylation and activation of the 
E3 ubiquitin ligase Itch which specifically ubiquitinates c-
FLIP and induces its proteasomal degradation. Thus, JNK 
antagonizes NF-κB during TNF-α signaling by promoting 
the proteasomal elimination of c-FLIPL [25].
Akt, a serine-threonine kinase, interacts with c-
FLIPL protein and c-FLIPL enhances the anti-apoptotic 
functions of Akt [55, 56] by modulating Gsk3β activ-
ity. Moreover, through its effects on Gsk3β, c-FLIPL 
overexpression in cancer cells induces resistance 
to TRAIL. This effect is mediated by regulation 
of p27 (Kip1) and caspase-3 expression [56]. Down-
regulation of the DNA-PK/Akt pathway is also reported 
to correlate with high responsiveness to TRAIL-me-
diated growth inhibition and apoptosis [57]. siRNA-
mediated suppression of DNA-PK or treatment with 
4,5-dimethoxy-2-nitrobenzaldehyde (DMNB), an in-
hibitor of DNA-PK, led to decreased phosphorylation 
of Akt and Bad (a target molecule of Akt), increased 
expression of DR4/DR5, and downregulation of c-FLIP 
[57]. Therefore, inhibition of the DNA-PK/Akt pathway 
may be clinically useful in treating TRAIL-resistant 
cancer cells [58].
Fig. 3. Multifunctional roles of c-FLIP on various signaling path-
ways. As discussed in the text, in addition to its functional role 
in inhibiting apoptosis by binding to procaspases-8 and -10 and 
inhibiting their activation, c-FLIP activates various anti-apoptotic 
and cell survival signaling pathways, leading to proliferation and 
cell survival
Panner et al. [59] demonstrated that a novel phos-
phatase and tensin homologue (PTEN)-Akt-atrophin-
interacting protein 4 (AIP4) pathway regulates c-FLIPS 
ubiquitination and stability in GBM cell lines and 
xenografts. However, how PTEN and Akt are linked 
to AIP4 activity was unclear. These authors described 
a second regulator of ubiquitin metabolism, the 
ubiquitin-specific protease 8 (USP8), which is a down-
stream target of Akt, and how it links Akt to AIP4 and 
the regulation of c-FLIPS stability [60]. Overexpression 
of USP8 increased c-FLIPS ubiquitination, decreased 
c-FLIPS half-life, decreased c-FLIPS steady-state lev-
els, and decreased TRAIL resistance. Therefore, PTEN 
appears to use control of ubiquitination to regulate 
TRAIL sensitivity in GBM cells.
c-FLIPL also interacts with the death domain-associ-
ated protein Daxx and prevents Fas-induced JNK acti-
vation [61]. Thus, c-FLIPL acting on both the FADD- and 
Daxx-mediated signaling pathways may be involved 
in inhibiting Fas-induced cell death. Furthermore, c-
FLIPL directly interacts with a JNK activator, MAP kinase 
kinase 7 (MKK7), in a TNF-α-dependent manner and 
inhibits the interactions of MKK7 with MAP/ERK kinase 
kinase 1 (MEKK1), apoptosis signal-regulating kinase 
1, (ASK1) and TGF-β-activated kinase 1. This interac-
tion of c-FLIPL with MKK7 might selectively suppress 
JNK activation [62] (see Fig. 3).
Another regulator of c-FLIP upregulation is calci-
um/calmodulin-dependent protein kinase II (CaMK II), 
which protects cancer cells from TRAIL-induced 
apoptosis. Treating resistant cells with the CaMK 
II inhibitor KN-93 inhibited CaMK II activity, reduced 
c-FLIP expression, inhibited c-FLIP phosphorylation, 
and rescued Fas agonistic antibody (CH-11) sensitivity 
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[63, 64]. Phosphorylation of c-FLIP variants by CaMK 
II appears to promote c-FLIPL recruitment to the DISC 
and inhibit TRAIL-induced apoptosis [63, 64], but 
phosphorylation of c-FLIPL by PKC or the bile acid 
glycochenodeoxycholate results in decreased c-FLIPL 
recruitment to the DISC [65]. Thus, the particular site 
of phosphorylation on c-FLIPL appears to influence the 
functional effect of this protein on apoptosis. It has been 
shown that calmodulin (CaM) binds directly to c-FLIPL 
in a calcium-dependent manner and prevents Fas-trig-
gered apoptosis [66]. Interestingly, a point mutation 
at H204 of c-FLIPL markedly decreases CaM binding 
[67]. Therefore, inhibition of CaM/c-FLIP interaction 
may provide a new therapeutic strategy for cancer 
treatment.
Overexpression of c-FLIP can alter cell cycle 
progression and enhance cell proliferation and carci-
nogenesis [68, 69]. Increased expression of c-FLIPL 
inhibited the ubiquitination and proteasomal degrada-
tion of β-catenin, resulting in an increase in the target 
gene cyclin D1, colony formation, and invasive activity 
in prostate cancer cells. The c-FLIP/β-catenin/cyclin 
D1 signals contributing to colony formation and inva-
sion were reversed by selective silencing of c-FLIP 
expression [70]. Similarly, c-FLIPL, in cooperation with 
FADD, enhances canonical Wnt signaling by inhibiting 
proteasomal degradation of β-catenin, thus suggest-
ing an additional mechanism of tumorigenesis [70]. 
Moreover, a role for nuclear c-FLIPL in modulating 
Wnt signaling has been established [71]. Interestingly, 
a deficiency of the adenomatous polyposis coli (APC) 
gene and subsequent activation of β-catenin can also 
lead to repression of c-FLIP expression through activa-
tion of c-Myc [72], c-FLIP upregulation may contribute 
to the carcinogenesis and aggressiveness of endo-
metrial carcinomas and serve as a useful prognostic 
factor for this tumor [71, 73]. c-FLIP overexpression 
is also significantly related to the presence of high-risk 
human papillomavirus (HR-HPV) infection during the 
progression of cervical squamous cell cancer, and 
c-FLIP is an early marker of cervical carcinogenesis 
[74]. Moreover, HPV16 E2 protein interacts with and 
abrogates the apoptosis inhibitory function of c-FLIP 
and renders cervical cancer cell lines hypersensitive 
to Fas/FasL apoptosis. This observation may be useful 
for developing therapeutic strategies to silence c-FLIP 
for intervention with cervical carcinogenesis [75]. 
Overexpression of c-FLIPL also increases hypoxia-in-
ducible factor-1α (HIF1α) [76]. In turn, overexpression 
of HIF1α can result in regulation of genes responsible 
in cell proliferation, metastasis, and invasion. More-
over, c-FLIP overexpression accelerated progression 
to androgen independence by inhibiting apoptosis 
in LNCaP prostate tumors implanted in nude mice [77].
Much evidence has clearly demonstrated that c-
FLIPS plays a major role in causing resistance to death 
ligands and chemotherapeutic agents. Park et al. [78] 
reported that MEK1/2 inhibitors synergistically interact 
with the heat shock protein 90 (HSP90) inhibitor and 
geldanamycins [17-allylamino-17-demethoxygeldana-
mycin (17AAG) and 17-dimethylaminoethylamino-17-de-
methoxygeldanamycin] to kill hepatoma and pancreatic 
carcinoma cells. Treating cells with MEK1/2 inhibitors 
and 17AAG reduced expression of c-FLIPS that was 
connected to loss of MEK1/2 and AKT function. More-
over, overexpression of c-FLIPS or inhibition of cas-
pase-8 abolished cell killing by MEK1/2 inhibitors and 
17AAG. Interestingly, Panner et al. [79] reported that 
HSP90α recruits c-FLIPS to the DISC and contributes 
to TRAIL resistance. Furthermore, combinations 
of sorafenib and vorinostat increased CD95 surface 
levels and CD95 association with caspase-8, and 
knockdown of CD95 or FADD expression reduced 
sorafenib/vorinostat-induced cell death [80]. Signaling 
by CD95 caused protein kinase R (PKR)-like endo-
plasmatic reticulum kinase (PERK) activation that was 
responsible for both promoting caspase-8 associa-
tion with CD95 and increased eIF2α phosphorylation. 
Suppression of eIF2α function abolished sorafenib/
vorinostat lethality. Cell death was paralleled by PERK- 
and eIF2α-dependent reduction of c-FLIPs protein 
levels, while overexpression of c-FLIPS maintained cell 
viability [80]. Similarly, expression of phosphorylation-
insensitive eIF2α-S51A blocked sorafenib- and vorino-
stat-induced suppression of c-FLIPS levels and over-
expression of c-FLIPS [81]. Overexpression of c-FLIPS 
also suppressed cell death by the multinuclear platinum 
chemotherapeutic BBR3610 [82].
c-FLIP as a therapeutic target for cancer 
treatment. c-FLIP can serve as a critical target for 
therapeutic intervention aimed at inhibiting its tran-
scription and posttranscriptional changes [11, 16]. 
Ectopic expression of c-FLIP variants decreases 
apoptosis caused by death ligands and anticancer 
agents [24], indicating that overexpression of these 
proteins may cause resistance to multiple anticancer 
drugs. It does not appear possible to inhibit c-FLIP 
function with small molecule ligands since c-FLIP has 
significant structural similarity to caspase-8 (Fig. 2). 
This resemblance to caspase-8 makes c-FLIP protein 
a very difficult target for drugs to inhibit its function, 
since small molecules capable of blocking its recruit-
ment to the DISC would also likely inhibit recruitment 
of caspase-8, thereby inhibiting apoptosis. Therefore, 
to reduce or inhibit c-FLIP expression, small molecules 
which target c-FLIP without inhibiting caspases-8 and 
-10 are needed. Several review articles have discussed 
classes of agents that decrease c-FLIP expression and 
sensitize cancer cells to TRAIL or anticancer drugs [11, 
16, 18, 83]. These agents affect c-FLIP transcription, 
trigger c-FLIP degradation through the ubiquitin-
proteasome system, or decrease c-FLIP translation. 
Moreover, DNA damaging agents are promising drugs 
with regard to downregulating levels of c-FLIP variants. 
Pretreatment with chemotherapeutic drugs including 
cisplatin, doxorubicin, or topoisomerase I inhibitors 
(camptothecin, 9-NC, irinotecan) downregulates c-
FLIP variants expression in various tumor cells by in-
hibiting its transcription and rendering cells sensitive 
to death receptor-triggered apoptosis [84–90].
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Several histone deacetylase inhibitors (HDACi) 
have been shown to significantly downregulate c-FLIP 
expression in various cancer cells at the transcriptional 
and translational levels [11, 91–94]. Among these, 
suberoylanilide hydroxamic acid (SAHA, vorinostat) 
is the most promising HDACi that causes robust 
inhibition of c-FLIP variants [91]. TRAIL-triggered 
apoptosis in breast cancer cells was blocked at the 
level of apical activation of caspase-8, and SAHA en-
hanced the TRAIL-induced processing and activation 
of procaspase-8. Interestingly, degradation of c-FLIPL 
and c-FLIPS by a ubiquitin/proteasome-dependent 
Itch/AIP4-independent mechanism is observed upon 
exposure to SAHA [91]. We recently showed that a new 
HDACi, 4-(4-chloro-2-methylphenoxy)-N-hydroxybu-
tanamide (CMH) [93] or droxinostat [94], identified 
using a high-throughput chemical library screen [95, 
96], triggered apoptosis in the breast cancer cell line 
MCF-7 through c-FLIPL and c-FLIPS mRNA as well 
as protein downregulation [93]. Interestingly, this 
agent induced more robust apoptosis in a doxorubicin-
resistant variant of MCF-7 cells [93]. Among c-FLIP 
inhibitors, histone deacetylase inhibitors have been 
very effective agents. Particularly significant is the 
recent discovery by Kerr et al. [97] reporting a novel 
interaction between c-FLIP and Ku70, a key compo-
nent of non-homologous end joining machinery in the 
DNA damage pathway in the HCT-116 human colon 
cancer cell line. Interestingly, Ku70 regulates c-FLIP 
protein stability by inhibiting its polyubiquitination 
[97]. Moreover, these authors showed that vorinostat 
(SAHA) increased the acetylation of Ku70, thereby 
disrupting the c-FLIP/Ku70 complex and initiating 
c-FLIP polyubiquitination and degradation by the pro-
teasome. Furthermore, the HDAC6-specific inhibitor 
Tubacin mimicked the effects of SAHA, suggesting 
that HDAC6 is a critical regulator of Ku70 acetylation 
and c-FLIP protein stability [97]. 
Small molecule therapeutics that selectively down-
regulate c-FLIPS or c-FLIPL and gene therapy strategies 
that knock down a specific c-FLIP variant have been 
used to downregulate these variants. Developing these 
innovative therapeutic strategies in conjunction with 
TRAIL and chemotherapeutic agents could potentially 
overcome the barrier of dose-limiting toxicity in cancer 
chemotherapy. TRAIL or chemotherapy resistance in di-
verse cancer cell types can be reversed by parallel treat-
ment with agents known to downregulate c-FLIP variants.
CONCLUSIONS
Accumulating evidence shows that c-FLIP vari-
ants induce resistance to death receptor ligands and 
chemotherapeutic agents in various cancer cells. 
Moreover, c-FLIP upregulation correlates with a poor 
clinical outcome and could be a reliable prognostic 
factor in several types of cancer. Therefore, c-FLIP iso-
forms may be a relevant clinical target for counteracting 
therapy-resistant human malignancies. Various classes 
of agents can downregulate c-FLIP expression. Since 
c-FLIP has significant structural similarity to caspase-8, 
it is very difficult to target c-FLIP directly since small 
molecules capable of blocking the recruitment of c-FLIP 
to the DISC could simultaneously inhibit the recruitment 
of caspase-8 and thereby inhibit apoptosis. Therefore, 
to reduce or inhibit c-FLIP expression, small molecules 
which target c-FLIP without inhibiting caspases-8 and 
-10 are needed. Compounds that inhibit or downregu-
late c-FLIP mRNA expression or cause degradation 
of c-FLIP at the protein level through proteasome deg-
radation will be of particular interest.
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